combination of active agents for the treatment of progressive fibrous interstitial lung diseases (pf-ild)

摘要

the present invention relates to a combination treatment / combination drug for the treatment of pf-ild, comprising, as a first combination partner, a therapeutically effective amount of nintedanib or a pharmaceutically acceptable salt thereof and, as a second combination partner, a therapeutically effective amount of a pde4b inhibitor of formula (i), where ring a is a 6-membered aromatic ring that can optionally comprise one or two nitrogen atoms and where r is cl and where r can be located in the para-, meta- or ortho- position of ring a, where s * is a sulfur atom that represents a chiral center or a pharmaceutically acceptable salt thereof. here, the second combination partner is preferably a therapeutically effective amount of the pde4b inhibitor of formula iii or a pharmaceutically acceptable salt thereof.